menu
    • menu
    [{"orgOrder":0,"company":"Cranbury Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Deflazacort","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Cranbury Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Cranbury Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cranbury Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Cranbury Pharmaceuticals

    Menu

    Cranbury Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cranbury Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Cranbury Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deflazacort

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cranbury Receives FDA Approval for First Generic Emflaza Oral Suspension

                            Details : Emflaza-Generic (deflazacort) is a corticosteroid prodrug, which acts through the glucocorticoid receptor as an agonist. It is approved for the treatment of duchenne muscular dystrophy.

                            Brand Name : Emflaza-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 12, 2024

                            Lead Product(s) : Deflazacort

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth